Savient makes executive appointments
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals is strengthening its management team with three new appointments as it begins the commercial launch of its gout therapy Krystexxa (pegloticase). Louis Ferrari will join as senior vice-president of North America commercial, Christine Mikail will become senior vice-president of corporate development and Stephen Davies becomes chief information officer and group vice president. Mr Ferrari was previously as vice-president of oncology and nephrology, sales and marketing at Centocor Ortho Biotech; Ms Mikail served as vice-president, general counsel and secretary for ImClone Systems; while Mr Davies was also previously at ImClone, where he as vice-president of information technology.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip